Novartis Ag (NVS) closed at $160.20 on November 16, 2026, down 0.2% from the previous close, on volume of 1,369,880 shares (30-day average 1,957,950).
Data as of November 16, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Put Spread | 20-Nov-26155 : 160 P | 5,602 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 16, 2026. See the largest for 5, 30, 60 and 90 days
SCHD, VYMI, or VIG: Which Dividend ETF Fits In Your Portfolio?
TipRanks (Tue, 17-Nov 11:12 AM ET)
Novartis' Cosentyx wins FDA approval for polymyalgia rheumatica
Seeking Alpha News (Tue, 17-Nov 7:24 AM ET)
Novartis Files Documents Tied to Four-Series Notes Issuance
TipRanks (Thu, 12-Nov 5:16 PM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
PRNewswire (Thu, 15-Oct 10:02 AM ET)
Big Pharma Setbacks Create a New Wave of Rebound Plays
Globe Newswire (Thu, 10-Sep 2:12 PM ET)
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
Globe Newswire (Thu, 10-Sep 8:30 AM ET)
PRNewswire (Wed, 9-Sep 1:24 PM ET)
Market Chameleon (Fri, 27-Feb 4:23 AM ET)
Here's what history shows about NVS past earnings run-ups
Market Chameleon (Fri, 11-Jul 7:42 AM ET)
NVS Pre-Earnings History Points to a Sharp Rally
Market Chameleon (Wed, 23-Apr 6:15 AM ET)
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Novartis Ag trades on the NYSE stock market under the symbol NVS.
As of November 17, 2026, NVS stock price declined to $159.08 with 884,793 million shares trading.
NVS has a beta of 0.06, meaning it tends to be less sensitive to market movements. NVS has a correlation of 0.00 to the broad based SPY ETF.
NVS has a market cap of $300.44 billion. This is considered a Mega Cap stock.
Last quarter Novartis Ag reported $15 billion in Revenue and $2.46 earnings per share. This fell short of revenue expectation by $-35 million and exceeded earnings estimates by $.22.
In the last 3 years, NVS traded as high as $170.46 and as low as $92.35.
The top ETF exchange traded funds that NVS belongs to (by Net Assets): DFIV, DFAI, DFIC, AVDE, DIHP.
NVS has outperformed the market in the last year with a price return of +24.8% while the SPY ETF gained +10.0%. NVS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +5.4% and -1.5%, respectively, while the SPY returned -5.5% and -2.7%, respectively.
NVS support price is $157.48 and resistance is $162.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVS shares will trade within this expected range on the day.